Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Shares Issued (2022 - 2025)

Historic Shares Issued for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $2.5 million.

  • Stoke Therapeutics' Shares Issued rose 168992.81% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 29904.84%. This contributed to the annual value of $1.7 million for FY2024, which is 21027.03% up from last year.
  • Per Stoke Therapeutics' latest filing, its Shares Issued stood at $2.5 million for Q3 2025, which was up 168992.81% from $554000.0 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Shares Issued registered a high of $2.5 million during Q3 2025, and its lowest value of $1000.0 during Q4 2023.
  • In the last 4 years, Stoke Therapeutics' Shares Issued had a median value of $250000.0 in 2022 and averaged $492357.1.
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 8080.0% in 2023, then soared by 5660000.0% in 2024.
  • Stoke Therapeutics' Shares Issued (Quarter) stood at $151000.0 in 2022, then crashed by 99.34% to $1000.0 in 2023, then skyrocketed by 56600.0% to $567000.0 in 2024, then soared by 338.8% to $2.5 million in 2025.
  • Its Shares Issued was $2.5 million in Q3 2025, compared to $554000.0 in Q2 2025 and $1.0 million in Q1 2025.